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Chimaeric toxins have considerable therapeutic potential to treat
various malignancies. We have previously used the fungal
ribonucleolytic toxin restrictocin to make chimaeric toxins in
which the ligand was fused at either the N-terminus or the C-
terminus of the toxin. Chimaeric toxins containing ligand at the
C-terminus of restrictocin were shown to be more active than
those having ligand at the N-terminus of the toxin. Here we
describe the further engineering of restrictocin-based chimaeric
toxins, anti-TFR(scFv)–restrictocin and restrictocin–anti-
TFR(scFv), containing restrictocin and a single chain fragment
variable (scFv) of a monoclonal antibody directed at the human
transferrin receptor (TFR), to enhance their cell-killing activity.
To promote the independent folding of the two proteins in the
chimaeric toxin, a linear flexible peptide, Gly-Gly-Gly-Gly-Ser,
was inserted between the toxin and the ligand to generate
restrictocin–linker–anti-TFR(scFv) and anti-TFR(scFv)–linker–
INTRODUCTION
The lethal potential of plant and bacterial toxins has been used
extensively to generate immunotoxins and chimaeric toxins for
targeted therapy [1–5]. Immunotoxins and chimaeric toxins
consist of potent protein toxins linked to targeting ligands by
chemical coupling or gene fusion technology. The bacterial
toxins Pseudomonas exotoxin A (PE) and diphtheria toxin (DT)
have been used successfully for making active immunotoxins and
chimaeric toxins, which have undergone preclinical and clinical
trials [2,6]. Immunotoxins containing the plant toxin ricin have
also shown great promise in clinical trials ; however, the gen-
eration of plant recombinant immunotoxins is lagging behind [1].
Because recombinant immunotoxins are made by gene fusion
technology, certain constraints are inherent in their constructions
in terms of the orientation of ligand and the toxin in the fusion
protein. With PE, a ligand has to be attached at the N-terminus,
whereas a free N-terminus is absolutely essential for the cyto-
toxicity of DT and ligands have to be placed at its C-terminus
[7,8]. Chimaeric toxins bind specifically to the cell-surface target ;
after internalization, the toxin is translocated to the intracellular
target to manifest its cytotoxic activity via different routes for
different toxins [1,6]. The PE and DT containing chimaeric
toxins are cleaved proteolytically inside the cell ; a translocation-
competent and enzymically active fragment of toxin thus released
acts on its intracellular target [9–11]. The ricin-A-chain-based
chimaeric toxins with direct gene fusions of ligand and toxin
were found to be functionally inactive ; however, the insertion of
Abbreviations used: DT, diphtheria toxin ; FvLR, anti-TFR(scFv)–linker–restrictocin ; FvSR, anti-TFR(scFv)–spacer–restrictocin ; FvR, anti-
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restrictocin. A 12-residue spacer, Thr-Arg-His-Arg-Gln-Pro-
Arg-Gly-Trp-Glu-Gln-Leu, containing the recognition site for
the protease furin, was incorporated between the toxin and the
ligand to generate restrictocin–spacer–anti-TFR(scFv) and anti-
TFR(scFv)–spacer–restrictocin. The incorporation of the pro-
teolytically cleavable spacer enhanced the cell-killing activity of
both constructs by 2–30-fold depending on the target cell line.
However, the introduction of linker improved the cytotoxic
activity only for anti-TFR(scFv)–linker–restrictocin. The prot-
eolytically cleavable spacer-containing chimaeric toxins had
similar cytotoxic activities irrespective of the location of the
ligand on the toxin and they were found to release the restrictocin
fragment efficiently on proteolysis in itro.
Key words: chimaeric toxins, protease, protein engineering,
targeting, toxins.
an intervening specific protease recognition site made them
cytotoxic [12,13]. Chimaeric toxins are being explored as alterna-
tive modality for the treatment of diseases such as cancers, HIV
infection, autoimmune disorders and various neural disorders
[1,4,5,14]. The results indicate therapeutic efficacy; however,
dose-dependent systemic toxicity and immunogenicity are now
being recognized as the major hurdles in their exclusive use
[2,3,15]. There is therefore always a need to explore novel toxins
with desirable properties that could be readily used as com-
ponents of chimaeric toxins with any potential targeting ligand.
Restrictocin, a specific ribonuclease produced by the fungus
Aspergillus restrictus, belongs to a family of ribosome-inact-
ivating proteins classified as ribotoxins. a-Sarcin and mitogillin
are two other well-characterized members of the ribotoxin family
[16]. These proteins share considerable amino acid sequence
similarity and inhibit protein synthesis by specifically cleaving a
single phosphodiester bond in 23 S and 28 S rRNA of prokaryotic
and eukaryotic ribosomes [17,18]. The fungal ribotoxins do not
bind to any cell-surface receptors but manifest a potent cytotoxic
activity if introduced inside the cell by artificial means [19].
Restrictocin has been successfully employed to make active
immunotoxins [20–24]. Its small size, poor immunogenicity,
absence of a cell-binding activity and thermostability make it a
desirable candidate for constructing chimaeric toxins [24].
We have recently developed restrictocin-based chimaeric toxins
by placing transforming growth factor a or the single-chain-
antigen-combining region (scFv) of an anti-(human transferrin
receptor) (anti-TFR) antibody separately at the N-terminus and
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C-terminus of the toxin [25,26]. Although both N-terminal and
C-terminal fusions had similar ribonucleolytic activity in itro,
cell-surface binding activity and intracellular routing, their
cytotoxic activities were remarkably different [26]. Chimaeric
toxins containing ligand at the C-terminus of the restrictocin
were found to be more potent than those that had ligand at the
N-terminus of the toxin [25,26]. It was therefore shown that
the preferred site of direct ligand attachment on restrictocin was
its C-terminus, which might become a limitation for employing
restrictocin universally with any potential ligand for the con-
struction of chimaeric toxins [25,26]. By using protease inhibitors
it has been shown that, after internalization, restrictocin-based
chimaeric toxins are cleaved proteolytically [26]. The difference
between the cytotoxic activities of N-terminal and C-terminal
fusion proteins was therefore proposed to be due to a difference
in their intracellular proteolytic processing [26].
Here we describe the construction and characterization
of second-generation chimaeric toxins comprising restrictocin
and anti-TFR(scFv). Anti-TFR(scFv)–restrictocin and restric-
tocin–anti-TFR(scFv) have been further engineered to enhance
their cell-killing activity. To facilitate folding and, in turn,
the intracellular processing of restrictocin-containing chimaeric
toxins, we have incorporated between the ligand and the
toxin either a flexible peptide linker or a proteolytically cleavable
spacer. The study demonstrates that with a proteolytically cleav-
able spacer, ligand can be placed at either end of restrictocin
and that restrictocin-based chimaeric toxins containing a proteo-
lytically cleavable spacer between the toxin and the ligand are
much more potent.
EXPERIMENTAL
Construction of plasmids
All gene fusions were cloned in a phage T7 promoter-based
Escherichia coli expression vector, pVex11. pVex11 is a pET-
derived vector that was kindly provided by Professor V. K.
Chaudhary (University of Delhi, Delhi, India). pRestrictocin–
anti-TFR(scFv) (pRFv) and pAnti-TFR(scFv)–restrictocin
(pFvR) were used as parent vectors for further manipulations
[26]. The primers were designed to introduce the linker or the
spacer by PCR. E. coli strain DH5a was used to propagate and
manipulate plasmid DNA. The plasmids having the required
gene fusions were identified by restriction analysis and protein
expression. The presence of the linker and the spacer was
confirmed by DNA sequencing with Sanger ’s method [27].
pRestrictocin–linker–anti-TFR(scFv) (pRLFv)
A linker, coding for the pentapeptide Gly-Gly-Gly-Gly-Ser, was
incorporated between the restrictocin and scFv genes. The linker
sequence was introduced at the 3« end of the restrictocin gene by
PCR with a previously described plasmid, pRest [28], as the
template, which contains the restrictocin gene under T7 promoter
as an NdeI–EcoRI fragment. The forward primer XUP (5«-
ACTCACTATAGGGAGACCAC-3«) annealed upstream of the
restrictocin-encoding gene in the promoter region of the vector.
The reverse primer A2 (5«-GTCATCGTACTCATATGGGAT-
CCCCCACCGCCATGAGAACACAG-3«) was designed to
provide a DNA sequence encoding a Gly
%
Ser linker at the 3« end
of restrictocin and an NdeI restriction site. The amplified
fragment, restrictocin–linker, was digested with NdeI and ligated
into plasmid pRFv, digested with the same enzyme, in place of
restrictocin to generate pRestrictocin–linker–anti-TFR(scFv).
pAnti-TFR(scFv)–linker–restrictocin (FvLR)
The DNA encoding the pentapeptide linker was incorporated at
the 5« end of the restrictocin gene by PCR with pRest as the
template. The forward primer A1 (5«-ATGTCTGTAGCATATG
GGCGGGGGTGGATCCGCGACCTGGACATGC-3«) pro-
vided the linker sequence and an NdeI site ; the reverse primer
JSR3 (5«-TGTTAGCAGCCGAATTCAATGAGAACACAG-
3«), containing an EcoRI site, annealed downstream of the
restrictocin-encoding gene in the vector. Linker–restrictocin,
obtained after PCR, was digested with NdeI and EcoRI and
cloned into the vector pFvR, digested with the same enzymes, in
place of the restrictocin fragment [26].
pRestrictocin–spacer–anti-TFR(scFv)
A spacer sequence encoding amino acid residues Thr-Arg-His-
Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu was engineered
between restrictocin and anti-TFR(scFv) to provide a protease
recognition site. The 36 bp spacer was introduced at the 3« end of
restrictocin by two consecutive PCRs with pRest as the template
in the first PCR, and the product of the first PCR as the tem-
plate in the second PCR. In the first PCR, a sequence encoding the
first eight amino acids of spacer was incorporated and the spacer
was extended to its full length in the second PCR. Primer XUP
(sequence mentioned above) was the forward primer for both the
first and the second PCR and the reverse primers used were: A3
(5«-GCCTCGAGGCTGGCGATGACGGGTATGAGAAC-
ACAG-3«) for the first PCR and A4 (5«-TGATTAGATACT
CATATGCAGTTGTTCCCAGCCTCG AGGCTG-3«) for the
second PCR. After the second PCR, the amplified fragment
contained the gene encoding restrictocin with the 36 bp spacer at
its 3« end. The fragment was digested with NdeI and ligated into
pRFv, digested with the same enzyme, in place of the restrictocin
fragment.
pAnti-TFR(scFv)–spacer–restrictocin (FvSR)
The spacer coding sequence was incoporated at the 5« end of
the restrictocin gene by two consecutive PCRs with JSR3 as the
reverse primer and the following forward primers : DR3
(5«-CAGCCGCGCGGCTGGGAACAACTGGCGACCTGG-
ACA-3«) for the first PCR and DR4 (5«-ATCTTACGC-
CATATGACCCGTCATCGCCAGCCGCGCGGC-3«) for the
second PCR. pRest was the template in the first PCR;
the product of the first PCR was used as the template in the
second. The forward and reverse primers provided respectively an
NdeI and an EcoRI site on the 5« and 3« ends of the spacer-
containing restrictocin fragment. The amplified fragment was
digested with NdeI and EcoRI and ligated into pFvR, digested
with the same enzymes, in the place of the restrictocin fragment.
Expression and purification of chimaeric toxins
A competent BL21(kDE3) strain of E. coli cells was transformed
separately with different constructs and grown in superbroth at
37 °C containing 100 lg}ml ampicillin. The cultures were in-
duced, at a D
'!!
of 2.0, with 1 mM isopropyl b-d-thiogalacto-
pyranoside for 2 h. The fusion proteins were overexpressed
and were found to localize in inclusion bodies. The proteins from
inclusion bodies were purified as described [29]. The inclusion
bodies were denatured with 6 M guanidinium chloride, reduced
with dithioerythritol and renatured in a buffer containing arginine
and GSSG. The renatured protein, after dialysis in 20 mM Mes,
pH 5.5, was loaded on an SP-Sepharose column (Pharmacia)
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Figure 1 Schematic representation of restrictocin-based chimaeric toxins
In RLFv and FvLR a flexible peptide linker (L1), and in RSFv and FvSR a proteolytically cleavable spacer sequence (S), is incorporated between restrictocin and anti-TFR(scFv) in the chimaeric
toxins. L, linker between the variable heavy chain and the variable light chain of anti-TFR antibody. Amino acids (single-letter codes) in bold capitals represent the connecting peptide sequences.
The proteolytic cleavage site in the spacer is shown by an arrow.
and eluted with a 0–1 M NaCl gradient on an FPLC system
(Pharmacia). Proteins were further purified by gel-exclusion
chromatography on a TSK 3000SW column and analysed by
SDS}PAGE [12% (w}v) gel] under reducing conditions. The
concentration of purified proteins was estimated by Bradford’s
method [30] with Coomassie plus reagent (Pierce). SDS}PAGE
was performed by the method of Laemmli [31].
Characterization of proteins by CD spectroscopy
CD spectra of proteins dissolved in 50 mM sodium phosphate
buffer, pH 7.4, were recorded in the far-UV range at 25 °C with
a Jasco J710 spectropolarimeter.
Cell-free assay of inhibition of protein synthesis
Ribonucleolytic activity of restrictocin, in chimaeric toxins, was
assessed in a translation assay in itro containing rabbit
reticulocyte lysate. Rabbit reticulocyte lysate was prepared, and
assay done, as described [32]. Various concentrations of chimaeric
toxins and restrictocin were incubated with rabbit reticulocyte
lysate for 1 h at 30 °C; the reaction was terminated by the
addition of 1 M NaOH containing H
#
O
#
. The translated product
was precipitated with 20% (w}v) trichloroacetic acid and the
radiolabelled protein was harvested on glass fibre filters and
counted in a liquid-scintillation counter.
Assay of cytotoxicity and specificity of chimaeric toxins
Protein synthesis was measured in a variety of cell lines in the
absence or presence of the toxins. All cell lines were maintained
in RPMI medium containing 10% (v}v) fetal calf serum.
Adherent cells were plated in 96-well flat-bottomed tissue culture
plates at 5¬10$ cells per well and allowed to adhere overnight at
37 °C. Next day, the medium was removed and replaced with
200 ll of leucine-free RPMI medium containing 10% serum.
Suspension cells were seeded at 5¬10$ cells per well in leucine-
free RPMI medium containing 2% (v}v) fetal calf serum and
used immediately. Serial dilutions of proteins, made in PBS
containing 0.2% (v}v) human serum albumin, were added to the
cells, incubated for the indicated durations and then pulsed with
[$H]leucine (1 lCi per well) for 3 h. Cells were harvested on filter
mats and the incorporation of [$H]leucine into cellular protein
was assayed with an LKB Beta-Plate counter. To check the
specificity of chimaeric toxins for TFR, 10 lg of anti-TFR
antibody (HB21) was added to each well before the addition of
fusion protein in the competition experiments.
Binding studies
Competition binding analysis was performed to compare the
affinity of the chimaeric toxins with the native antibody. Anti-
TFR antibody (HB21) was iodinated by the Iodogen method
[33]. Adherent A549 and A431 cells were seeded at 4¬10& cells
per well and used 16 h later for the assay. HUT102 cells were also
plated at the same density and used immediately. After two
washes with binding buffer (0.1% BSA in Dulbecco’s modified
Eagle ’s medium), various dilutions of toxin, along with 3 ng of
labelled antibody in binding buffer, were added to the cells. The
cells were incubated at 25 °C for 2 h with mild shaking, washed
three times with binding buffer and lysed in 10 mM Tris}HCl
(pH 7.4)}1 mM EDTA}0.5% SDS. The radioactivity associated
with the cells was counted in a c-counter (LKB).
RESULTS
Construction of chimaeric toxins
We have previously developed two chimaeric toxins, anti-
TFR(scFv)–restrictocin and restrictocin–anti-TFR(scFv), in
which the Fv portion of a monoclonal antibody against human
TFR was genetically fused respectively at the N-terminus and the
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Figure 2 SDS/PAGE of purified restrictocin-based chimaeric toxins
The purified proteins were analysed by SDS/PAGE [12.5% (w/v) gel] stained with Coomassie
Blue. The positions of molecular mass markers are indicated (in kDa) at the left. Lane 1, FvR ;
lane 2, FvLR ; lane 3, FvSR ; lane 4, RFv ; lane 5, RLFv ; lane 6, RSFv ; lane 7, restrictocin.
C-terminus of ribonucleolytic toxin restrictocin [26].
Restrictocin–anti-TFR(scFv) was more active than anti-
TFR(scFv)–restrictocin on all the target cell lines [26]. It was
therefore concluded that for restrictocin-based chimaeric toxins
to be optimally active, ligand should be placed at the C-terminus
of the toxin. To improve the activity of restrictocin-based
chimaeric toxins, anti-TFR(scFv)–restrictocin and restrictocin–
anti-TFR(scFv) were further engineered by incorporating be-
tween ligand and toxin (1) a flexible peptide linker Gly-Gly-Gly-
Gly-Ser or (2) a proteolytically cleavable spacer Thr-Arg-His-
Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu. The proteolytically
cleavable spacer used in this study was derived from domain II
of PE; PE is cleaved intracellularly by a protease within this
sequence between Arg and Gly, to generate a 37 kDa trans-
location-competent fragment [9,34]. On the basis of biochemical
studies a serine protease, furin, has been proposed to be
responsible for this cleavage [11,35–38]. PE is also cleaved in itro
by trypsin at the same location to produce the 37 kDa fragment
Figure 3 CD-spectral analysis of restrictocin-based chimaeric toxins
A cell with a 1 cm path was used to record the spectra of proteins. Spectra were acquired at a scan speed of 50 nm/min with a sensitivity of 0.050 ° and a response time of 1 s. The samples
were purged with nitrogen and spectra were averaged over 10 accumulations. Mean residue ellipticity is expressed in units of m-degrees[cm2[dmol−1. (A) Solid line, RFv ; dotted line, RLFv ; broken
line, RSFv. (B) Solid line, FvR ; dotted line, FvLR ; broken line, FvSR.
[34,37]. A schematic representation of gene fusions encod-
ing FvLR, FvSR, restrictocin–linker–anti-TFR(scFv) (RLFv)
and restrictocin–spacer–anti-TFR(scFv) (RSFv) is shown in
Figure 1.
The gene fusions were cloned in a T7 promoter-based E. coli
expression vector. After expression in E. coli, the proteins
accumulated in the form of inclusion bodies within the cell. The
recombinant proteins were isolated from the inclusion bodies by
denaturation in guanidinium hydrochloride; after renaturation
they were purified to homogeneity by successive cation-exchange
and gel-filtration chromatography (Figure 2).
To investigate the effect of introducing a flexible peptide linker
or a cleavable spacer between the ligand and restrictocin on their
conformation, the chimaeric toxins were analysed by CD spec-
troscopy. Restrictocin–anti-TFR(scFv) (RFv), previously shown
to have a potent cytotoxic activity, seemed to have a compactly
folded a­b structure (Figure 3A), whereas RLFv and RSFv,
although similar to each other, were significantly different in
conformation from RFv (Figure 3A). Among the chimaeric
toxins in which the ligand was placed on the N-terminus of
restrictocin, FvLR seemed to be compactly folded similarly to
RFv; however, anti-TFR(scFv)–restrictocin (FvR) and FvSR
were not optimally folded (Figure 3B).
Effect of chimaeric toxins on protein synthesis in vitro
Previously we found that fusing a ligand either at the N-terminus
or at the C-terminus of restrictocin drastically affected the
ribonucleolytic activity of restrictocin: the chimaeric proteins
were approx. 1}30 as active as the native toxin [26]. To investigate
the effect of introducing a spacer or a linker between the ligand
and the toxin on the catalytic activity, the ribonucleolytic activity
of chimaeric toxins was tested in a translation assay in itro
containing rabbit reticulocyte lysate. All constructs inhibited
protein synthesis in a dose-dependent manner, with doses giving
half-maximal inhibition (ID
&!
) ranging between 1 and 2 nM, in
comparison with 0.07 nM for restrictocin (Table 1). There was
no significant improvement in the ribonucleolytic activity in itro
of restrictocin containing chimaeric toxins as a result of the
incorporation of a flexible linker or a cleavable spacer between
the ligand and the toxin (Table 1).
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Table 1 Effect of restrictocin-based chimaeric toxins on translation in
vitro
Rabbit reticulocyte lysate was treated with various concentrations of different proteins at 30 °C
for 1 h. Protein synthesis was determined by measuring the incorporation of [3H]leucine into
newly synthesized proteins.
Chimaeric toxin ID50 (nM)
FvR 1.50
FvLR 1.01
FvSR 0.88
RFv 2.05
RLFv 2.25
RSFv 0.91
Restrictocin 0.07
Figure 4 Toxicity of chimaeric toxins towards HUT102 cell line
The cytotoxic activity of chimaeric toxins is plotted as the percentage inhibition of protein
synthesis relative to the untreated control after 48 h. Cells were incubated with various
concentrations of chimaeric toxins as follows : (A) N-terminal constructs FvR (D,E), FvLR
(*,+) or FvSR (^,_) ; (B) C-terminal constructs RFv (x,y), RLFv (V,U) or RSFv (Y,
[). The open and closed symbols represent the chimaeric toxin tested in the absence and the
presence respectively of excess of anti-TFR antibody.
Cytotoxicity and specificity of chimaeric toxins
The cytotoxic activity of chimaeric toxins was tested on a variety
of human cancer cell lines overexpressing TFR. The fusion
proteins inhibited protein synthesis in the target cell lines in a
dose-dependent manner (Figure 4 and Table 2). As shown in
Figure 4 for HUT102 cells, the addition of an excess of anti-TFR
antibody blocked the manifestation of toxicity by these fusion
proteins. The incomplete neutralization observed at the highest
chimaeric toxin concentrations seemed to be due to a lower
antibody-to-toxin ratio. Similar results were obtained on all
target cell lines studied, demonstrating that all chimaeric toxins
were specifically recognizing the TFR. All fusion proteins were
non-toxic to a mouse fibroblast cell line, L929, producing no
inhibition of protein synthesis even at 112 nM, indicating the
species-specific binding of the proteins to TFR. Restrictocin
alone, up to 100 nM, did not inhibit protein synthesis in any of
the cell lines studied (results not shown). All chimaeric toxins
exhibited maximum activity on HUT102, a T-cell leukaemia cell
line (Table 2). FvSR and RSFv were 28-fold and 12-fold more
cytotoxic than FvR and RFv respectively (Table 2). FvLR, in
comparison with that of FvR, showed a 9-fold higher cytotoxicity
Table 2 Cytotoxicity of restrictocin-based chimaeric toxins on various
cancer cell lines
Human cancer cell lines HUT102 (T-cell leukaemia), K562 (erythroleukaemia), A549 (lung
carcinoma), COLO205 (colon adenocarcinoma), MCF7 (breast adenocarcinoma),
A431 (epidermoid carcinoma) and HeLa (cervical carcinoma), and a mouse fibroblast cell line,
L929, were used.
ID50 (nM)
Cell line FvR FvLR FvSR RFv RLFv RSFv
HUT102 0.17 0.02 0.006 0.06 0.07 0.005
K562 1.14 0.14 0.12 0.14 0.54 0.08
A549 0.80 0.23 0.13 0.14 0.29 0.10
COLO205 1.45 0.23 0.13 0.27 0.45 0.14
MCF7 2.27 0.47 0.22 0.36 0.67 0.16
A431 5.00 0.38 0.16 0.61 0.83 0.40
HeLa 8.20 0.82 0.89 0.98 2.20 1.10
L929 " 114 " 112 " 111 " 114 " 112 " 111
towards the same cell line. The incorporation of the Gly-Gly-
Gly-Gly-Ser linker between Fv and restrictocin resulted in a
3–13-fold increase in the activity of Fv-restrictocin on all cell
lines tested (Table 2). In contrast, RLFv was found to have an
activity that was either marginally decreased or similar to that of
RFv on all target cell lines (Table 2). The incorporation of the
cleavable spacer Thr-Arg-His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-
Gln-Leu improved the activity of FvR remarkably and that of
RFv marginally on all cell lines (Table 2). FvSR and RSFv
had almost similar cytotoxic activities towards all target cells
(Table 2).
Binding of chimaeric toxins to TFR
To check whether the differences in cytotoxicity of various
proteins were due to a difference in the binding affinities of these
constructs for TFR, the binding activities of these chimaeric
toxins were compared with that of native antibody towards
HUT102, A431 and A549 cells. All the proteins were found to be
equally potent in displacing the native anti-TFR monoclonal
antibody from the three cell lines studied (Figure 5). Restrictocin,
used as a non-specific control, showed no competition with
native antibody even at the 100-fold higher concentration (results
not shown).
Susceptibility of chimaeric toxins to trypsin-mediated cleavage
From our previous study it was evident that, to manifest their
cytotoxic activity, restrictocin-based chimaeric toxins needed to
be processed proteolytically [26]. In the present study it was
found that the incorporation of a proteolytically cleavable spacer
in these chimaeric toxins improved their cytotoxicity significantly.
To investigate the susceptibility of various chimaeric toxins to
proteolytic cleavage, and to locate the cleavage site, the fusion
proteinswere treated with trypsin at pH 7.4 for various durations.
Two major fragments, of 27 and 16 kDa, were obtained by a
limited trypsin digestion of spacer-containing chimaeric toxins
(Figure 6A). The 16 kDa fragment, corresponding to restrictocin,
was also obtained from FvR and RFv, but in a very small
quantity, indicating a relatively inefficient processing of
these proteins (Figure 6A). The digestion of the spacer-containing
proteins was complete within 15 min, whereas all other
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Figure 5 Binding of chimaeric toxins to target cell lines
Iodinated anti-TFR antibody mixed with various concentrations of the unlabelled antibody or various chimaeric toxins was incubated with indicated cell line. Binding analyses was performed with
the following : (A) N-terminal constructs FvR (^), FvLR (D) or FvSR (*) or unlabelled antibody (V) ; (B) C-terminal constructs RFv (^), RLFv (D) or RSFv (*) or unlabelled antibody (V).
fusion proteins were comparatively resistant to the protease : even
after a prolonged incubation only a very faint 16 kDa band was
detected (results not shown). However, no non-specific degrad-
ation was visible even after prolonged treatment with trypsin. A
similar pattern was observed when the proteins were digested at
pH 5.25 (results not shown).
The fragments produced were characterized by Western blot-
ting by probing with an anti-restrictocin antibody. The 16 kDa
band released from RSFv and FvSR corresponded to restrictocin
(Figure 6B). After digestion, RLFv produced a band that reacted
with anti-restrictocin antibody and had a higher molecular mass
than that of restrictocin and the 16 kDa band released from
RSFv and FvSR (Figures 6A and 6B). The site of cleavage
in spacer-containing chimaeric toxins was ascertained by N-
terminal sequence analysis of the two fragments obtained;
the cleavage was found to be occurring precisely at the predicted
cleavage site producing the 27 kDa scFv fragment and 16 kDa
restrictocin fragment (results not shown).
Kinetics of intoxication by restrictocin-containing chimaeric toxins
To investigate the kinetics of intoxication bydifferent restrictocin-
containing chimaeric toxins, their cytotoxic activity was assayed
onHUT102,K562 andA431 cells at various time points (Table 3).
The cell lines that were more sensitive to the spacer-containing or
linker-containing chimaeric toxins were used as model cell lines
for this study. As reported previously, FvR and RFv showed
potent cytotoxicity only after 36–48 h, whereas RSFv and FvSR,
chimaeric toxins containing the cleavable spacer, manifested
potent cytotoxic activity starting at 24 h (Table 3). This shift in
kinetics was observed for all the cell lines studied (Table 3),
indicating that the protease responsible for the cleavage of these
chimaeric toxins was present ubiquitously. In addition, with the
protease cleavage site present in the chimaeric toxins, they were
processed efficiently to release a translocation-competent active
fragment of restrictocin intracellularly. Of the linker-containing
proteins, FvLR also showed the peak activity earlier ; however,
the kinetics of RLFv was similar to that of RFv (Table 3).
DISCUSSION
Restrictocin, a member of the fungal ribotoxin family, is a
promising candidate for the construction of immunotoxins and
chimaeric toxins [20–22,24–26]. Ribotoxins ’ inability to enter the
normal cells, their stability and their low immunogenicity are
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Figure 6 Sensitivity of restrictocin-based chimaeric toxins to trypsin-
mediated cleavage
Restrictocin and restrictocin-based chimaeric toxins were digested in 25 mM Hepes, pH 7.4,
containing 1 mM CaCl2 and 0.5 mM EDTA. Trypsin (500 ng) was added to 1 lg of protein and
the samples were incubated at 37 °C for 30 min. The reaction was terminated by the addition
of SDS/PAGE sample buffer. The samples were analysed by SDS/PAGE on 12% (w/v) reducing
gels and detected by staining with Coomassie Blue. (A) SDS gel stained with Coomassie Blue.
(B) Western blot probed with a polyclonal anti-restrictocin antibody. Lanes 1, FvR ; lanes 2,
FvLR ; lanes 3, FvSR ; lanes 4, RFv ; lanes 5, RLFv ; lanes 6, RSFv ; lane 7, restrictocin. The
positions of molecular mass markers are indicated (in kDa) at the left. The ligand, anti-TFR(scFv)
and restrictocin fragments produced as a result of digestion of the restrictocin-based intact
chimaeric toxins are indicated by arrows at the right.
some of the desirable characteristics for their use in the con-
struction of chimaeric toxins. Gasset et al. [39,40] have shown
that a-sarcin interacts with negatively charged phospholipid
vesicles, which could be a mechanism for its intracellular trans-
location. The cytotoxic activity of restrictocin containing
chimaeric toxins and immunotoxins supports the contention that
restrictocin is translocation-competent [20–26]. The crystal struc-
ture of restrictocin revealed that the surface of the molecule is
dome-shaped and that the active site is located on the planar side
[41]. The N-terminus and C-terminus of the molecule are linked
by a disulphide bond (Cys&–Cys"%() [41]. The structure therefore
Table 3 Kinetics of cytotoxicity of restrictocin-based chimaeric toxins
HUT102, K562 and A431 cells, at a density of 5¬104 cells/ml, were incubated with different concentrations of chimaeric toxins for indicated durations; protein synthesis was assayed by measuring
the incorporation of [3H]leucine into newly synthesized protein.
ID50 (ng/ml)
HUT102 K562 A431
Chimaeric toxin Duration (h)… 24 36 48 24 36 48 24 36 48
FvR 150 7 16 " 1000 600 70 " 1000 550 500
FvLR 20 1.5 2.5 100 30 4.5 220 60 16
FvSR 5 0.5 0.8 57 22 4.2 200 25 10
RFv 37 2 3.5 350 35 13 600 100 60
RLFv 55 25 5 250 42 18 800 140 140
RSFv 1 0.3 0.3 35 13 4.5 250 60 40
does not put any apparent constraint on putting a ligand on
either of the termini of restrictocin for developing a chimaeric
toxin. However, it has been shown previously that the
chimaeric toxins with a ligand at the C-terminus were invariably
more active on all the cell lines studied than their N-terminal
counterparts [25,26]. These studies implied that the differential
cytotoxicity was due to (1) a difference in the intracellular
processing and}or (2) a difference in the translocation of the
enzymically active moiety in the cytosol. The difference in activity
could also be attributed to simple differences in folding of
the two constructs. The present study was aimed at designing
restrictocin-based chimaeric toxins with improved cytotoxic ac-
tivity and to make restrictocin a universal toxin such that a ligand
could be placed at either of the two termini without compromising
the activity. A linear flexible linker, Gly-Gly-Gly-Gly-Ser,
was incorporated between the ligand [anti-TFR(scFv)] and
the toxin (restrictocin) to promote the independent folding of the
two proteins in the chimaera. The introduction of the linker
improved the activity of only the chimaera inwhich the ligand was
attached at the N-terminus of restrictocin and made it as active as
RFv, the chimaera with the ligand at the C-terminus of restric-
tocin. Thus the ligand could also be attached at the N-terminus
of restrictocin with an intermediary linker sequence. However,
RLFv had a decreased activity in comparison with FvR, in-
dicating that the linker was detrimental to the activity of RFv
and that the linker could not be used universally at either end to
construct chimaeric toxins with restrictocin. The conformations
of RFv and FvLR, which had similar cytotoxic activities, were
also very similar, indicating that an improvement in the activity
with the incorporation of the linker was due to an improvement
in the folding of the molecule.
It was demonstrated previously that a non-cleavable immuno-
toxin, generated by chemically coupling a monoclonal antibody
against human TFR to restrictocin through a stable linkage, was
inactive on most of the cell lines, whereas the cells were sensitive
towards a cleavable conjugate constructed from the same anti-
body and restrictocin [24]. In addition, in the presence of the
protease inhibitor tosyl-lysylchloromethane (‘TLCK’), the cyto-
toxicities of FvR and RFv were significantly diminished, indi-
cating the involvement of a protease in the cytotoxicity of these
chimaeric toxins [26]. Recombinant chimaeric toxins containing
PE and DT are processed proteolytically to produce trans-
location-competent active fragments to manifest their cyto-
toxicity [9–11]. A cellular protease, furin, is responsible for the
proteolytic processing of these toxins [11]. The furin recognition
sequence in PE is present within the disulphide loop between
Cys#'( and Cys#)( in the translocation domain [9,34]. In the
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present study we incorporated the peptide sequence Thr-Arg-
His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu from PE, contain-
ing the furin recognition site, between the ligand and the toxin in
restrictocin-containing chimaeric toxins to facilitate the intra-
cellular processing of these proteins. The inclusion of the
proteolytically cleavable spacer resulted in a marked increase in
the activity of both types of chimaeric toxin, indicating that
processing is important in the manifestation of activity by these
chimaeric toxins. RSFv and FvSR had similar cytotoxicities
towards all the cell lines studied and they were equally active as,
or more active than, RFv. In itro, both RSFv and FvSR were
processed in a similar manner by trypsin. It is seen that the
cytotoxicity is manifested by the chimaeric toxins from which a
full-length (16 kDa) restrictocin fragment is released in itro by
digestion with trypsin. RLFv produced a fragment that was
larger than the restrictocin fragment, and correspondingly the
cytotoxicity of this chimaera was much lower. Without a spacer
or a linker, although the fusion proteins are processed to release
the restrictocin fragment, the processing seems to be much less
efficient. A shift in the kinetis of intoxication by the spacer-
containing chimaeric toxins also shows that efficient intracellular
processing is required for restrictocin-based immunotoxins to be
optimally active. The study demonstrates that for restrictocin-
containing chimaeric toxins to be active they need to be folded
such that a full-length restrictocin fragment is released from
them by intracellular proteolytic processing. The proteolytically
cleavable spacer-containing chimaeric molecules are processed
efficiently and precisely within the spacer, although from the CD
spectral analysis they seem not to be optimally folded. The furin
recognition sequence might be exposed on the surface in these
chimaeric toxins and therefore accessible to the protease. Pre-
viously, chimaeric toxins have been produced containing the
ricin A chain and Protein A linked via a trypsin-sensitive spacer
sequence from DT, to produce disulphide-linked ricin A chain
and Protein A by proteolytic activation [12]. Although this
chimaera is active, it needs to be nicked proteolytically in itro
before its addition to the target cells [12]. The proteolytically
cleavable spacer sequence used in this study is efficiently processed
by all the cell lines studied without any prior activation in itro.
In conclusion, we have designed and developed the next
generation of restrictocin-containing immunotoxins with
improved biological activity ; it should now be possible to use
restrictocin for the construction of immunotoxin with any
potential targeting ligand.
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